The overexpression of ERCC4 led to decreased sensitivity to cisplatin (Fig. 2M, P and Fig. S2M, N) and reduced DNA damage (Fig. 2N, Q and Fig. S2O, P) in bladder cancer cells. This evidence concerns the gene ERCC4 and urinary bladder carcinoma.